Nachrichten March 10, 2016

Shearman & Sterling Advises on Sinco Pharmaceuticals’ Hong Kong IPO

Shearman & Sterling advised Sinco Pharmaceuticals Holdings Limited (Sinco Pharmaceuticals) on its global offering and initial public offering (IPO) on the Main Board of The Stock Exchange of Hong Kong Limited.  China Merchants Securities (HK) Co., Limited acted as the sole sponsor, sole global coordinator, sole bookrunner and sole lead manager.

Sinco Pharmaceuticals is the third largest provider of marketing, promotion and channel management services in the PRC pharmaceutical industry.

Over the past year, Shearman & Sterling’s Hong Kong capital markets team advised on significant Hong Kong listings in the healthcare industry, including the first-ever PRC specialty hospital group IPO by Harmonicare Medical Holdings in July 2015 followed by Wenzhou Kangning Hospital’s primary listing in November 2015, the second such PRC specialty hospital group IPO in the market.

The Team

Praxisgruppen

Industrien